Skip to main content

Akoya Biosciences, Inc.

AKYADelisted
Industry
Laboratory Analytical Instruments
SEC CIK
0001711933

Akoya Biosciences, Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 10, 2025; 58 institutions reported holding it in 13F filings for Q2 2025, worth $16.3M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Akoya Biosciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Akoya Biosciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Akoya Biosciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Shepler Robert GDirector369,592IndirectJul 10, 20250
Lai Goldman MylaDirector0Jul 10, 20250
Schnettler Thomas PDirector2,742,721IndirectJul 10, 20250
Raffin Thomas A.Director0IndirectJul 10, 20250
Mendel ScottDirector0Jul 10, 20250
Winkler MatthewDirector0Jul 10, 20250
Ek John FrederickCFO0IndirectJul 10, 20250
Ramachandran Niro Ph.DChief Business Officer0Jul 10, 20250
McKelligon BrianPresident and CEO0Jul 10, 20250
Kamocsay JenniferChief Legal Officer0Jul 10, 20250
Bamford PascalChief Clinical Officer0Jul 10, 20250
Pla FredericChief Operating Officer101,500Mar 25, 20240
Nolan Garry Ph.D.Director555,084Jun 5, 20230
Moy MarileeCHIEF PEOPLE OFFICER20,000Feb 27, 20230
El-Gabry EhabChief Medical Officer16,250Feb 27, 20230
Driscoll JosephChief Financial Officer262,500Dec 27, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 12, 2024 (view filing)4:01 PM ETJun 111 dayMcKelligon BrianPresident and CEOSSale−7.50K$2.08−$15.6K−3.2%224.7K after10b5-1
Jun 7, 2024 (view filing)9:56 PM ETJun 61 dayMcKelligon BrianPresident and CEOSSale−7.50K$2.01−$15.1K−3.2%224.7K after10b5-1
Mar 22, 2024 (view filing)5:54 PM ETMar 202 daysMcKelligon BrianPresident and CEOSSale−7.50K$4.97−$37.2K−3.1%231.9K after10b5-1
Mar 22, 2024 (view filing)5:51 PM ETMar 139 daysMcKelligon BrianPresident and CEOSSale−7.50K$4.94−$37.0K−3.1%231.9K afterAmended10b5-1
Dec 20, 2023 (view filing)7:16 PM ETDec 191 dayMcKelligon BrianPresident and CEOSSale−7.50K$4.48−$33.6K−4.7%152.6K after10b5-1
Dec 14, 2023 (view filing)4:24 PM ETDec 122 daysMcKelligon BrianPresident and CEOSSale−7.50K$4.25−$31.9K−4.7%152.6K after10b5-1
Nov 22, 2023 (view filing)4:00 PM ETNov 202 daysMcKelligon BrianPresident and CEOSSale−7.50K$4.39−$32.9K−4.7%152.6K after10b5-1
Sep 11, 2023 (view filing)Sep 74 daysPla FredericChief Operating OfficerPPurchase+20.0K$4.60+$92.0KNew position20.0K after2 lots
Jun 12, 2023 (view filing)Jun 12Same dayEk John FrederickCFOPPurchase+20.0K$5.00+$100.0KNew position20.0K afterDuplicate filing
Jun 12, 2023 (view filing)Jun 12Same dayLai Goldman MylaDirectorPPurchase+20.0K$5.00+$100.0KNew position20.0K after
Jun 12, 2023 (view filing)Jun 12Same dayMendel ScottDirectorPPurchase+20.0K$5.00+$100.0K+235.3%28.5K after
Jun 12, 2023 (view filing)Jun 12Same dayWinkler MatthewDirectorPPurchase+203.4K$5.00+$1.02M+26.0%984.5K after
Jun 12, 2023 (view filing)Jun 12Same dayShepler Robert GDirectorPPurchase+120.0K$5.00+$600.0K+48.1%369.6K after
Jun 12, 2023 (view filing)Jun 12Same dayRaffin Thomas A.DirectorPPurchase+2.02M$5.00+$10.1M+14.5%15.9M after3 lots
Jun 6, 2023 (view filing)9:45 PM ETJun 6Same dayMcKelligon BrianPresident/CEOSSale−5.00K$5.71−$28.5K−3.2%152.6K after10b5-1
Mar 27, 2023 (view filing)Dec 13, 2022104 daysNolan Garry Ph.D.DirectorSSale−100$13.25−$1.32K0.0%555.1K afterAmended
Mar 16, 2023 (view filing)4:20 PM ETMar 142 daysMcKelligon BrianPresident/CEOSSale−5.00K$9.17−$45.9K−3.0%160.0K after2 lots
Dec 20, 2022 (view filing)Dec 137 daysLateSchnettler Thomas PDirectorSSale−71.0K$13.03−$925.8K−2.5%2.74M after
Dec 16, 2022 (view filing)5:59 PM ETDec 142 daysDriscoll JosephChief Financial OfficerSSale−24.6K$12.54−$308.7K−66.3%12.5K after2 lots
Dec 8, 2022 (view filing)4:01 PM ETDec 62 daysMcKelligon BrianPresident/CEOSSale−5.00K$12.08−$60.4K−5.9%80.0K after
Dec 6, 2022 (view filing)Dec 24 daysNolan Garry Ph.D.DirectorSSale−1.10K$13.25−$14.6K−0.2%592.0K after
Dec 2, 2022 (view filing)Dec 11 dayNolan Garry Ph.D.DirectorSSale−5.00K$13.36−$66.8K−0.8%593.1K after
Nov 17, 2022 (view filing)Nov 161 dayNolan Garry Ph.D.DirectorSSale−300$13.25−$3.98K−0.1%598.1K after
Nov 14, 2022 (view filing)Nov 10-144 daysNolan Garry Ph.D.DirectorSSale−24.4K$13.29−$324.5K−3.9%598.4K after3 lots
Sep 16, 2022 (view filing)Sep 142 daysNolan Garry Ph.D.DirectorSSale−8.30K$13.26−$110.1K−1.3%622.8K after
Sep 13, 2022 (view filing)Sep 9-124 daysNolan Garry Ph.D.DirectorSSale−24.0K$13.31−$319.3K−3.7%631.1K after2 lots
Sep 9, 2022 (view filing)4:00 PM ETSep 72 daysMcKelligon BrianPresident/CEOSSale−5.00K$12.83−$64.2K−5.9%80.0K after
Jun 17, 2022 (view filing)4:08 PM ETJun 152 daysMcKelligon BrianPresident/CEOSSale−5.00K$10.25−$51.3K−5.9%80.0K after
Dec 13, 2021 (view filing)Dec 94 daysNolan Garry Ph.D.DirectorSSale−25.0K$12.67−$316.8K−3.7%655.1K after
Nov 22, 2021 (view filing)Nov 19-223 daysRamachandran Niro Ph.DChief Business OfficerPPurchase+25.1K$13.13+$329.2KNew position25.1K after2 lots
Nov 19, 2021 (view filing)Nov 19Same dayMendel ScottDirectorPPurchase+8.50K$13.16+$111.9KNew position8.50K after
Nov 18, 2021 (view filing)Nov 18Same dayShepler Robert GDirectorPPurchase+35.0K$12.60+$441.1KNew position35.0K after2 lots